Accumulation of ¹¹¹In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Coadministration of Targeting Ligand.

ABSTRACT: The successful use of targeted radionuclide therapy in the treatment of solid tumours may be limited by radioresistance, which necessitates delivery of a high dose of radioactivity. Nanoparticle (NP)-based delivery systems possess a large surface area for attachment of radioisotopes and so offer a solution to this challenge. However, tumour uptake may be limited by rapid hepatic clearance of NP via the mononuclear phagocyte system. Liver uptake is further compounded when epidermal growth factor (EGF) is used as a targeting ligand, as EGF-tagged NP bind the EGF receptor (EGFR), which is expressed to a moderate extent by hepatocytes. This report describes an indium-111 (¹¹¹In)-labelled PEGylated EGF-tagged gold (Au) NP (¹¹¹In-EGF-Au-PEG) and an effective strategy of coa

SUBMITTER: Song L 

PROVIDER: S-EPMC5646733 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature